Home › Compare › GRTS vs DIVO

GRTS vs DIVO: Dividend Comparison 2026

GRTS yields 6211.18% · DIVO yields 6.62%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GRTS wins by $514736922231177.94M in total portfolio value
10 years
GRTS
GRTS
● Live price
6211.18%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$514736922231177.94M
Annual income
$498,935,081,000,370,800,000.00
Full GRTS calculator →
DIVO
DIVO
● Live price
6.62%
Share price
$44.00
Annual div
$2.91
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.0K
Annual income
$1,008.47
Full DIVO calculator →

Portfolio growth — GRTS vs DIVO

📍 GRTS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGRTSDIVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GRTS + DIVO cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
GRTS pays
DIVO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GRTS
Annual income on $10K today (after 15% tax)
$527,950.31/yr
After 10yr DRIP, annual income (after tax)
$424,094,818,850,315,200,000.00/yr
DIVO
Annual income on $10K today (after 15% tax)
$562.67/yr
After 10yr DRIP, annual income (after tax)
$857.20/yr
At 15% tax rate, GRTS beats the other by $424,094,818,850,315,200,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GRTS + DIVO for your $10,000?

GRTS: 50%DIVO: 50%
100% DIVO50/50100% GRTS
Portfolio after 10yr
$257368461115588.97M
Annual income
$249,467,540,500,185,400,000.00/yr
Blended yield
96.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GRTS right now

GRTS
Analyst Ratings
7
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$4.67
+14403.1% upside vs current
Range: $3.00 — $6.00
Altman Z
-9.7
Piotroski
1/9
DIVO
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GRTS buys
0
DIVO buys
0
No recent congressional trades found for GRTS or DIVO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGRTSDIVO
Forward yield6211.18% ✓6.62%
Annual dividend / share$2.00$2.91 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$514736922231177.94M ✓$31.0K
Annual income after 10y$498,935,081,000,370,800,000.00 ✓$1,008.47
Total dividends collected$513674666624982.00M ✓$8.4K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: GRTS vs DIVO ($10,000, DRIP)

YearGRTS PortfolioGRTS Income/yrDIVO PortfolioDIVO Income/yrGap
1← crossover$631,818$621,118.01$11,362$661.96+$620.5K → GRTS
2$37,352,078$36,676,032.53$12,860$702.91+$37.34M → GRTS
3$2,066,348,794$2,026,382,070.58$14,504$743.56+$2066.33M → GRTS
4$106,978,454,906$104,767,461,696.78$16,303$783.73+$106978.44M → GRTS
5$5,183,619,185,269$5,069,152,238,519.27$18,268$823.31+$5183619.17M → GRTS
6$235,102,301,025,325$229,555,828,497,087.03$20,408$862.17+$235102301.00M → GRTS
7$9,981,906,672,630,884$9,730,347,210,533,788.00$22,737$900.20+$9981906672.61M → GRTS
8$396,781,870,195,426,800$386,101,230,055,711,700.00$25,266$937.31+$396781870195.40M → GRTS
9$14,768,075,916,642,124,000$14,343,519,315,533,017,000.00$28,008$973.42+$14768075916642.10M → GRTS
10$514,736,922,231,177,940,000$498,935,081,000,370,800,000.00$30,977$1,008.47+$514736922231177.94M → GRTS

GRTS vs DIVO: Complete Analysis 2026

GRTS — Stock

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Full GRTS Calculator →

DIVO — ETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →
📬

Get this GRTS vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GRTS vs SCHDGRTS vs JEPIGRTS vs OGRTS vs KOGRTS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.